US Pharma and Biotech Summit
The US biopharmaceutical industry faces relentless disruption. America still leads the world in high-risk drug development, and revolutionary treatments may shape a new era of healthcare. But the path from innovation to access is beset by uncertainty around policy, regulation and investment.
Stay informed and connected by attending the US Pharma and Biotech Summit 2026. Organized by FT Live in collaboration with Endpoints News, the event will bring together top executives, investors and experts to share powerful insights into the future of life sciences in America and worldwide.
.jpg)
THE EARLY BIRD
IN-PERSON PASS
Gain access to in-person sessions and networking drinks. Network and connect with your peers.
$2,329
Full price $2,849 from March 9th, 2026.
THE EARLY BIRD
DIGITAL PASS
Access to live talks, Q&A and video on demand. Join from the comfort of your home or office.
$359
Full price $459 from March 9th, 2026
Key Themes
Artificial intelligence in life sciences
Where is AI delivering return on investment for biopharma companies?
.png)
Dealmaking environment
Is dealmaking activity set to surge with rate cuts?
Clinical trial agility
How are industry-wide shifts in R&D affecting pipeline success rates?
Hear from leaders in Life Sciences
Why Attend?
Learn
how America's life sciences landscape is evolving in areas such as innovation, commercialization and regulation
Engage
with C-suite executives responsible for the big decisions in areas such as funding, workforce development and strategic partnerships
Enjoy
the opportunity to network with peers and build relationships in a friendly but focused environment
"I really enjoyed CEO insights. When you know what they are thinking we can design our strategies accordingly." - Vice President, Pfizer
Other Events
Speaking Opportunities
Ben Graham
ben.graham@ft.com
Sponsorship
Rachel Joy
rachel.joy@ft.com
Delegate Services
Hauwra Sharif
hauwra.sharif@ft.com
Join our mailing list
Stay up to date with the latest news, events and offers from FT Live.
© Financial Times Live
FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice
